Frazier Life Sciences Management L.P. Increases Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Frazier Life Sciences Management L.P. lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,069,754 shares of the biopharmaceutical company's stock after buying an additional 25,600 shares during the period. Agios Pharmaceuticals makes up 1.5% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 17th biggest position. Frazier Life Sciences Management L.P. owned 1.88% of Agios Pharmaceuticals worth $35,152,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Envestnet Asset Management Inc. raised its holdings in Agios Pharmaceuticals by 3.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after acquiring an additional 795 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $33,000. Vanguard Group Inc. lifted its position in Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after buying an additional 85,339 shares in the last quarter. Northern Trust Corp lifted its position in Agios Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock worth $19,567,000 after buying an additional 5,372 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Agios Pharmaceuticals by 48.8% during the fourth quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company's stock worth $8,725,000 after buying an additional 87,089 shares during the last quarter.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on AGIO shares. Scotiabank cut their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Finally, HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $56.00.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded up $0.21 during mid-day trading on Monday, reaching $29.80. 440,665 shares of the company's stock were exchanged, compared to its average volume of 695,398. The company's 50-day moving average is $28.66 and its 200-day moving average is $35.92. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 2.63 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.